Financial Performance - Sales for the three months ended March 31, 2025, increased by 52.4% to $28.694 million compared to $18.781 million for the same period in 2024[130] - Gross profit for the three months ended March 31, 2025, was $8.482 million, representing 29.6% of total sales, compared to $5.614 million or 29.8% in 2024[138] - Total operating expenses increased to $9.017 million, accounting for 31.4% of total sales, compared to $6.279 million or 33.4% in 2024[138] - The net loss for the three months ended March 31, 2025, was $393,000, or 1.4% of total sales, compared to a net loss of $487,000, or 2.6% in 2024[138] - Total sales increased by 52.4% to approximately $28.7 million for the three months ended March 31, 2025, compared to approximately $18.8 million for the same period in 2024[140] - Cost of sales rose by 53.0% to approximately $20.2 million for the three months ended March 31, 2025, from approximately $13.2 million for the same period in 2024[141] - Gross profit increased by 51.1% to approximately $8.5 million, representing 29.6% of sales for the three months ended March 31, 2025, compared to approximately $5.6 million, or 29.8% of sales, for the same period in 2024[143] - Operating expenses increased by 43.6% to approximately $9.0 million for the three months ended March 31, 2025, from approximately $6.3 million for the same period in 2024[144] - Net loss for the three months ended March 31, 2025, was approximately $0.4 million, compared to approximately $0.5 million for the same period in 2024[149] Revenue Sources - Program clients accounted for 83.8% of total revenue for the three months ended March 31, 2025, down from 86.0% in the same period of 2024[128] - The majority of revenue is derived from program business, with fewer than 350 of over 2,000 active customers classified as program clients[128] - The increase in sales for the Stran segment was primarily due to higher spending from existing clients and new customers[140] - The SLS segment's sales increase was attributed to the acquisition of the Gander Group Assets in August 2024[140] Assets and Equity - As of March 31, 2025, total assets were approximately $52.2 million, with total stockholders' equity of approximately $31.3 million[131] - Cash and cash equivalents as of March 31, 2025, were approximately $4.2 million, down from $9.5 million at the end of March 2024[150] - The Company had net deposits from reward card programs totaling approximately $0.9 million as of March 31, 2025[178] Operating Challenges - The company is facing challenges due to U.S. tariffs, particularly a reduction of tariffs on imports from China from 145% to 30% for 90 days, which may impact pricing and customer retention[129] Financing and Credit - The Revolving Line of Credit was capped at $7.0 million or 80% of Eligible Accounts plus 50% of Eligible Inventory, with a maximum of $2.0 million for advances based on Eligible Inventory[157] - The interest rate on the Revolving Line of Credit was set at the prime rate plus 0.5% per annum, with late payments incurring a 5.0% charge and a 10.0% increase in interest rate upon default[158][159] - The Company was required to maintain a minimum net worth of $2.0 million by December 31, 2021, increasing to $3.5 million by December 31, 2023[163] - As of the Termination Date on August 26, 2024, the Company had no funds drawn on the Revolving Line of Credit, which was subsequently terminated[168][169] - The Company acquired Gander Group assets for approximately $1.1 million in cash and assumed liabilities totaling approximately $5.5 million[171] - The Company must maintain a minimum liquidity of $7.5 million at all times, defined as cash and short-term investments[165] - The Company is required to maintain a "Minimum Interest Coverage" of 1.25:1 for the fiscal year ending December 31, 2024[165] Lease Obligations - The new office lease in North Quincy, Massachusetts, starting June 1, 2025, has an initial base rent of approximately $21,000 per month with annual escalations of 2.2% to 2.5%[175] - Future minimum lease payments total approximately $1.31 million, with $398,000 due in the remainder of 2025[177] Goodwill and Asset Impairment - The company conducts an annual impairment review of goodwill in the fourth fiscal quarter, assessing qualitative factors to determine potential impairment[182] - The impairment test for goodwill utilizes both the income approach and market approach, relying on significant estimates and assumptions regarding future financial performance[183] - Long-lived assets are assessed for impairment whenever events indicate that their carrying value may not be recoverable, considering factors such as significant underperformance and negative industry trends[184] - The fair value estimation for long-lived assets requires assumptions about future business prospects and market demand, which are subjective and complex[184] - Changes in assumptions and estimates regarding goodwill and long-lived assets could materially impact the company's reported financial results[184] - The company emphasizes the importance of judgment in evaluating impairment of both goodwill and long-lived assets, highlighting the subjective nature of these assessments[184] - The company’s carrying value for reporting units excludes certain corporate assets and liabilities, such as cash and debt, during fair value assessments[183] - The impairment review process is triggered by various factors, including significant changes in asset usage or overall business strategy[184] - The company’s financial statements include significant accounting policies and estimates that impact the valuation of goodwill and intangible assets[181] Compliance and Accounting Standards - The company qualifies as an "emerging growth company" under the JOBS Act, allowing it to rely on certain exemptions from disclosure requirements[132] - Recent accounting pronouncements are discussed in Note A.18 of the financial statements, indicating ongoing compliance with new accounting standards[185]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-41254 HWH INTERNATIONAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Financial Performance - Total revenue for the three months ended March 31, 2025, was $295,197, an increase from $286,110 in the same period of 2024, reflecting a growth of approximately 3.8%[166] - The net loss decreased significantly from $1,336,519 in Q1 2024 to $574,103 in Q1 2025, representing a reduction of about 57.0%[181] - Operating expenses decreased from $1,495,383 in Q1 2024 to $741,722 in Q1 2025, a decline of approximately 50.5%[179] - The cost of revenue increased from $122,813 in Q1 2024 to $147,603 in Q1 2025, resulting in a gross margin decrease from $163,297 to $147,594[178] Revenue Sources - Revenue from food and beverage sales accounted for approximately 100% of total revenue in both Q1 2025 and Q1 2024[166] - The geographical revenue distribution shifted, with 11% of total revenue coming from South Korea and 89% from Singapore in Q1 2025, compared to 4% and 96% in Q1 2024, respectively[167] Business Expansion - The company plans to expand its Hapi Marketplace, initially launching in the United States with over 47 product categories, and aims to expand to South Korea and Hong Kong soon[160] - Hapi Cafés are being developed as community-focused locations to enhance customer engagement and awareness of HWH products, with proof-of-concept locations opened in Seoul and Singapore[162] Financial Position - Cash decreased from $4,341,746 as of December 31, 2024, to $4,176,546 as of March 31, 2025, while total assets increased from $6,408,722 to $6,531,330 during the same period[182] - The Company reported no long-term debt obligations or liabilities as of March 31, 2025[199] Compliance and Regulatory Matters - The Company was notified by Nasdaq that its market value of publicly held shares was below the minimum $15,000,000 for 30 consecutive trading days, requiring compliance by August 20, 2024[194] - The Company received a notice from Nasdaq indicating that its bid price was below the minimum $1 required for continued listing, with a compliance deadline of March 3, 2025[196] - A 1-for-5 reverse stock split was filed on February 18, 2025, effective February 24, 2025[197] - The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price was $1.00 or greater from February 24, 2025 to March 7, 2025[198] Administrative and Financial Agreements - The Company agreed to pay $10,000 per month for administrative services, which ceased after the initial Business Combination[200] - The underwriters were entitled to a deferred fee of $3,018,750, which was settled with a combination of cash, shares, and a promissory note[202] Corporate Changes - The Business Combination was approved on August 1, 2023, and closed on January 9, 2024, resulting in the Company changing its name to "HWH International Inc."[204] - The Company is classified as an "emerging growth company," allowing it to take advantage of certain reporting exemptions[211] Internal Controls - Management assessed the effectiveness of internal controls over financial reporting as of March 31, 2025, identifying material weaknesses[216]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the quarterly period ended March 31, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ For the transition period from ____ to ____ Not applicable (Former name, former address and former fiscal year, if changed since last report) Commission file number: 001-38634 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number: 001-36259 Washington, D.C. 20549 NOVA LIFESTYLE, INC. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Nevada 90-0746568 (State or other jurisdiction of incorporation or organization) 6565 E. W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-36268 TNF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40458 SYNAPTOGENIX, INC. (Exact name of registrant as specified in its charter) (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-36268 TNF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 2 ...

Table of Contents For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value Enhanced · Four potentially transformative Preclinical · Leading programs focus on iPSC- programs engineered with industry- derived 'tunable' CD4+/CD8+ aß T cells Pipeline leading Allo-Evasion™ 5.0 Selective expansion to non-immune . Century effector cells in high impact diseases Therapeutics: Concentrating clinical focus with CNTY-101 on autoimmune disorders with transformational Clear focus on potential Concentrate ...